NCT03604978 2026-03-18
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
11 trialsNCT04317105 2026-03-18
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05896839 2026-03-18
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02696993 2025-11-10
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06866262 2025-09-09
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
University of Michigan Rogel Cancer Center
Phase 1/2 Recruiting
NCT02304458 2023-10-17
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT03326258 2018-07-18
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT03182816 2017-06-09
CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor
Shanghai Cell Therapy Research Institute
Phase 1/2 Unknown
NCT03179007 2017-06-07
CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor
Shanghai Cell Therapy Research Institute
Phase 1/2 Unknown
NCT00871481 2017-04-19
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed